Treats persistent facial erythema associated with rosacea. ANDA 213584, held by Sun Pharma Canada. Oxymetazoline Hydrochloride.
As of Nov 16, 2026, ANDA 213584 (Oxymetazoline Hydrochloride), held by Sun Pharma Canada, was first approved by FDA on Oct 4, 2021, with 0 approved supplements and 0 published complete response letters.
Oxymetazoline hydrochloride cream is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 4, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxymetazoline Hydrochloride1% · cream;topical | Oxymetazoline Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters